Interested in Vertex Pharmaceuticals Incorporated? Here are five stocks we like better.
Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $10 billion, paying $85 per share in cash, with closing expected in the third quarter of 2026.
The acquisition adds PALSONIFY, an approved acromegaly treatment, and Atumelant, a Phase 3 candidate for congenital adrenal hyperplasia, expanding Vertex's rare disease pipeline.
Analysts have not yet rerated VRTX shares since the announcement, though H.C. Wainwright maintains a Buy rating with a Street-high $641 price target.
Vertex Pharmaceuticals (NASDAQ: VRTX) recently announced its plans to acquire Crinetics Pharmaceuticals (NASDAQ: CRNX) for $10 billion. The deal, which has already been approved by the board of directors of both companies, is expected to close in the third quarter of 2026.
Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $10 billion, paying $85 per share in cash, with closing expected in the third quarter of 2026.
The acquisition adds PALSONIFY, an approved acromegaly treatment, and Atumelant, a Phase 3 candidate for congenital adrenal hyperplasia, expanding Vertex's rare disease pipeline.
Analysts have not yet rerated VRTX shares since the announcement, though H.C. Wainwright maintains a Buy rating with a Street-high $641 price target.
Vertex Pharmaceuticals (NASDAQ: VRTX) recently announced its plans to acquire Crinetics Pharmaceuticals (NASDAQ: CRNX) for $10 billion. The deal, which has already been approved by the board of directors of both companies, is expected to close in the third quarter of 2026.
24 days ago
